Top Story

Adalimumab associated with improvements in nail psoriasis

October 31, 2017

Twenty-six weeks of treatment with adalimumab was associated with improvements in a number of fingernail psoriasis outcomes compared with placebo, according to recent study findings.

In the phase 3 study, 217 patients with moderate-to-severe fingernail psoriasis and moderate-to-severe plaque psoriasis were randomly assigned 40 mg adalimumab every other week or placebo. There were 109 patients in the active therapy group and 108 patients in the placebo group.

IL-12 therapy elicits encouraging response rates in melanoma

October 25, 2017
Immunopulse IL-12 monotherapy and in combination with pembrolizumab was associated with encouraging response rates and safety data in patients with melanoma who may not…
Meeting News

Platelet-rich plasma injections efficacious for androgenetic alopecia

October 13, 2017
A monthly schedule of platelet-rich plasma injections was safe and efficacious in patients with androgenetic alopecia and may be preferable to injections administered…
In the Journals

UNCOVER-3: Taltz shows durability over long term

September 28, 2017
Patients with moderate-to-severe plaque psoriasis experienced a durable response to Taltz through 108 weeks, according to results of the UNCOVER-3 trial. The trial…
More Headlines »